The proposed US Most Favored Nation (MFN) policy has the potential to reshape global pricing and market access strategies, with implications extending across R&D, Business Development & Licensing, and Commercial functions.
Watch our recording to explore Simon-Kucher’s latest perspectives on the evolving MFN landscape. Our experts discuss the potential impact of the policy on global pricing and market access, as well as practical approaches to preparing commercial and P&MA strategies in an uncertain environment.
Participants will learn:
- The latest developments and our early perspectives on the potential impact of the US MFN policy on global P&MA and beyond
- How pharmaceutical and biotech companies need to prepare their P&MA strategies for the brave new MFN environment and how this will affect other corporate functions such as R&D, BD&L, and commercial
- Key considerations when designing and executing forward-looking P&MA research under changing MFN scenarios
